Docherty John P, Jones Robert, Turkoz Ibrahim, Lasser Robert A, Kujawa Mary
Comprehensive Neuroscience Inc., 21 Bloomingdale Road, White Plains, NY 10605, USA.
Community Ment Health J. 2007 Jun;43(3):267-80. doi: 10.1007/s10597-006-9081-4. Epub 2007 Mar 8.
We evaluated the usefulness of a treatment manual to facilitate the use of long-acting injectable risperidone in community mental health centers (CMHCs) during an open-label observational study. Perceived clinical utility and clinician adherence to the manual were evaluated. Patient adherence to treatment satisfaction, Clinical Global Impression of Severity (CGI-S) and the Schizophrenia Quality-of-Life Scale (SQLS) were assessed. Mean score for overall utility of the guidebook was 4.2 +/- .6 (scale ratings ranged from 1 = not at all to 5 = extremely). Most clinicians (89-100%) found the guidebook useful, and were adherent to key aspects of appropriate treatment use including concomitant oral risperidone use and injection and dosing parameters for long-acting risperidone. Most patients were adherent to treatment (86.7%), preferred long-acting risperidone over oral risperidone (72.6%) or other oral antipsychotics (78.4%) and were satisfied with long-acting risperidone (90.1%). The open-label observational design limits interpretation of these data. However, in this study manual-supported use of long-acting risperidone was associated with successful implementation of this pharmacologic treatment in the CMHC setting.
在一项开放标签观察性研究中，我们评估了一本治疗手册在社区心理健康中心（CMHCs）促进长效注射用利培酮使用的有效性。评估了手册的临床实用性以及临床医生对其的依从性。还评估了患者对治疗的依从性、满意度、临床总体印象严重程度量表（CGI-S）和精神分裂症生活质量量表（SQLS）。该指南手册总体实用性的平均得分为4.2±0.6（评分范围为1 = 完全无用至5 = 极其有用）。大多数临床医生（89 - 100%）认为该指南手册有用，并遵守了适当治疗使用的关键方面，包括同时使用口服利培酮以及长效利培酮的注射和给药参数。大多数患者坚持治疗（86.7%），相较于口服利培酮（72.6%）或其他口服抗精神病药物（78.4%），更倾向于长效利培酮，并且对长效利培酮感到满意（90.1%）。开放标签观察性设计限制了对这些数据的解读。然而，在本研究中，手册支持的长效利培酮使用与在CMHC环境中成功实施这种药物治疗相关。
